Standard curve
Example of Human Coagulation Factor XI standard curve in Assay Diluent A1.
Human Coagulation Factor XI OneStep ELISA Kit
Human Coagulation Factor XI OneStep ELISA Kit
Price:
Regular price
$500 USD
Regular price
Sale price
$500 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Antigen | Coagulation Factor XI |
| Immunogen | Recombinant Protein |
| Antibody Type | Recombinant mAb |
| Reactivity | Hu |
| Purification | Protein A |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8'C as supplied. |
Kit
| Precision | Intra-assay: 2.0%； Inter-assay: 3.5% |
| Sample type | Cell culture supernatant; Serum; Plasma-EDTA, Plasma-Citrate |
| Assay type | Sandwich (quantitative) |
| Sensitivity | 0.052 ng/mL |
| Range | 0.156 ng/mL – 10 ng/mL |
| Recovery | Cell culture supernatant: 89% Serum: 101% Plasma: 109% |
| Assay time | 60 minutes |
| Species reactivity | Hu |
Background
Human Coagulation Factor XI (FXI) is a plasma glycoprotein synthesized primarily in the liver and is a key zymogen within the intrinsic coagulation pathway. Upon activation by Factor XIIa, thrombin, or auto-activation, it converts to the serine protease Factor XIa. This active form then specifically cleaves and activates Factor IX, thereby amplifying the downstream coagulation cascade to generate thrombin and form a stable fibrin clot. Beyond its procoagulant role, FXI is also implicated in various thrombo-inflammatory processes. Notably, genetic deficiency of FXI results in a mild bleeding tendency known as hemophilia C, while elevated levels are considered a risk factor for thrombotic diseases like stroke and venous thromboembolism. Consequently, Factor XI is now a prominent therapeutic target, with inhibitors under development to create safer anticoagulants with potentially reduced bleeding risks.
Picture
Picture
ELISA
Linearity
The concentrations of Human Coagulation Factor XI were measured and interpolated from the target standard curves and corrected for sample dilution.
Sample is undiluted samples are as follows: HepG2 cell culture supernatant (50%). The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 2.96 ng/mL in HepG2 cell culture supernatant.
Linearity
The concentrations of Human Coagulation Factor XI were measured and interpolated from the target standard curves and corrected for sample dilution.
Sample is undiluted samples are as follows: Human serum was 500-fold dilution. The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 5.822 μg/mL in Human serum.
Sample is undiluted samples are as follows: Human plasma-EDTA was 500-fold dilution. The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 7.932 μg/mL in Human plasma-EDTA.
Sample is undiluted samples are as follows: Human plasma-Citrate was 500-fold dilution. The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 740.84 ng/mL in Human plasma-Citrate.
To assess the linearity of the assay, two samples were spiked with high concentrations of Human Coagulation Factor XI in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
To assess the linearity of the assay, sample was spiked with high concentrations of Human Coagulation Factor XI in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Specificity
Test the specificity of different serum.
Leading Competitor comparison
Protocol Diagram
